PMID- 26661925
OWN - NLM
STAT- MEDLINE
DCOM- 20170818
LR  - 20191210
IS  - 1600-0714 (Electronic)
IS  - 0904-2512 (Linking)
VI  - 45
IP  - 7
DP  - 2016 Aug
TI  - Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor 
      outcome in patients with salivary gland cancer.
PG  - 500-9
LID - 10.1111/jop.12394 [doi]
AB  - Fibroblast growth factor receptor 1 and 3 (FGFR1, FGFR3) impact on tissue 
      homoeostasis, embryonic development and carcinogenesis. Murine double minute 
      protein 4 (MDM4) and mouse double minute 2 homologue (MDM2) are regulators of 
      p53-protein and may be the origin of an apoptosis overpowering cascade. A 
      collective of 266 carcinomas of salivary glands were investigated for MDM2, MDM4, 
      FGFR1 and FGFR3 aberrations by fluorescence in situ hybridization (FISH). The 
      results were matched with clinicopathological parameters and with expression of 
      PTEN and p53. MDM2 gene amplification (n = 9) and chromosomal aberrations 
      (trisomy, n = 47; high polysomy, n = 7) are linked to high-grade malignancy (P < 
      0.001), lymph node metastasis (P = 0.001), advanced tumour size (P = 0.013) and 
      stage (P < 0.001), gender (P = 0.002) and age (P = 0.001). MDM4 gene 
      amplification (n = 19) and chromosomal aberrations (trisomy, n = 34; high 
      polysomy, n = 31) are correlated to high-grade malignancy (P < 0.001), lymph node 
      metastasis (P = 0.008), advanced tumour size (P = 0.039), stage (P = 0.004) and 
      loss of PTEN (P < 0.001). Only, high-grade malignancy (P < 0.001), lymph node 
      metastasis (P = 0.036) and advanced tumour stage (P = 0.025) are associated with 
      FGFR3 amplification (n = 1) or chromosomal aberrations (low polysomy, n = 61; 
      high polysomy, n = 55) but not with MDM4 alterations. FGFR1 amplifications (n = 
      5) and chromosomal aberrations (trisomy, n = 38; high polysomy, n = 30) are 
      associated with high-grade malignancy (P < 0.001), advanced tumour size (P = 
      0.026) and stage (P = 0.004), gender (P = 0.016) and age (P = 0.023). Aberrations 
      of MDM2, MDM4, FGFR1 and FGFR3 correlate with aggressive tumour growth and nodal 
      metastasis. MDM2 (P < 0.001), MDM4 (P = 0.005) and FGFR3 (P = 0.006) alterations 
      are associated with worse overall survival of patients with salivary gland 
      cancer.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Ach, Tobias
AU  - Ach T
AD  - Department of Oral and Maxillofacial Surgery, University of Regensburg, 
      Regensburg, Germany.
FAU - Schwarz-Furlan, Stephan
AU  - Schwarz-Furlan S
AD  - Institute of Pathology, Kaufbeuren, Germany.
FAU - Ach, Stephanie
AU  - Ach S
AD  - Department of Oral and Maxillofacial Surgery, University of Regensburg, 
      Regensburg, Germany.
FAU - Agaimy, Abbas
AU  - Agaimy A
AD  - Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
FAU - Gerken, Michael
AU  - Gerken M
AD  - Center of Tumor Registry, University of Regensburg, Regensburg, Germany.
FAU - Rohrmeier, Christian
AU  - Rohrmeier C
AD  - Department of Otorhinolaryngology, University of Regensburg, Regensburg, Germany.
FAU - Zenk, Johannes
AU  - Zenk J
AD  - Department of Otorhinolaryngology, Hospital of Augsburg, Augsburg, Germany.
FAU - Iro, Heinrich
AU  - Iro H
AD  - Department of Otorhinolaryngology, University of Erlangen-Nuremberg, Erlangen, 
      Germany.
FAU - Brockhoff, Gero
AU  - Brockhoff G
AD  - Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, 
      Germany.
FAU - Ettl, Tobias
AU  - Ettl T
AD  - Department of Oral and Maxillofacial Surgery, University of Regensburg, 
      Regensburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20151214
PL  - Denmark
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the International 
      Association of Oral Pathologists and the American Academy of Oral Pathology
JID - 8911934
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (MDM4 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Cell Cycle Proteins
MH  - Child
MH  - *Chromosome Aberrations
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lymphatic Metastasis
MH  - Mice
MH  - Middle Aged
MH  - Nuclear Proteins/*genetics
MH  - PTEN Phosphohydrolase/biosynthesis/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-mdm2/*genetics
MH  - Receptor, Fibroblast Growth Factor, Type 1/*genetics
MH  - Receptor, Fibroblast Growth Factor, Type 3/*genetics
MH  - Salivary Gland Neoplasms/*genetics/pathology
MH  - Tumor Suppressor Protein p53/biosynthesis/genetics
MH  - Young Adult
OTO - NOTNLM
OT  - FGFR1
OT  - FGFR3
OT  - MDM2
OT  - MDM4
OT  - prognosis
OT  - salivary gland cancer
EDAT- 2015/12/15 06:00
MHDA- 2017/08/19 06:00
CRDT- 2015/12/15 06:00
PHST- 2015/11/04 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2017/08/19 06:00 [medline]
AID - 10.1111/jop.12394 [doi]
PST - ppublish
SO  - J Oral Pathol Med. 2016 Aug;45(7):500-9. doi: 10.1111/jop.12394. Epub 2015 Dec 
      14.